Earth Science Tech (OTCMKTS:ETST) vs. Pyxis Oncology (NASDAQ:PYXS) Head-To-Head Comparison

Earth Science Tech (OTCMKTS:ETST) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Profitability

This table compares Earth Science Tech and Pyxis Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Earth Science Tech	6.67%	23.85%	13.57%
Pyxis Oncology	N/A	-38.34%	-30.01%

Earnings & Valuation

This table compares Earth Science Tech and Pyxis Oncology”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Earth Science Tech	$11.95 million	4.17	$810,000.00	N/A	N/A
Pyxis Oncology	N/A	N/A	-$73.79 million	($1.36)	-2.65

Earth Science Tech has higher revenue and earnings than Pyxis Oncology.

Risk and Volatility

Earth Science Tech has a beta of 1.82, suggesting that its stock price is 82% more volatile than the S&P 500. Comparatively, Pyxis Oncology has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500.

Institutional & Insider Ownership

39.1% of Pyxis Oncology shares are held by institutional investors. 24.9% of Earth Science Tech shares are held by insiders. Comparatively, 9.3% of Pyxis Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for Earth Science Tech and Pyxis Oncology, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Earth Science Tech	0	0	0	0	N/A
Pyxis Oncology	0	0	8	0	3.00

Pyxis Oncology has a consensus target price of $9.00, suggesting a potential upside of 149.31%. Given Pyxis Oncology’s higher probable upside, analysts clearly believe Pyxis Oncology is more favorable than Earth Science Tech.

Summary

Earth Science Tech beats Pyxis Oncology on 7 of the 10 factors compared between the two stocks.

About Earth Science Tech

Earth Science Tech, Inc. focuses on health and wellness industry. It operates men's health telemedicine platform under brand Peak name; and operates pharmacy. The company offers supplements and topicals products. The company was formerly known as Ultimate Novelty Sports, Inc. and changed its name to Earth Science Tech, Inc. in March 2014. Earth Science Tech, Inc. was incorporated in 2010 and is headquartered in Miami, Florida.

About Pyxis Oncology

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.